People who typically work much more than 35 to 40 hours a week may be at heightened risk of developing atrial fibrillation, an irregular rapid heartbeat that can lead to strokes, heart failure and chronic fatigue, a recent study suggests.

San Diego-based Arena Pharmaceuticals’ shares rocketed after positive data was announced from its Phase II clinical trial of a drug for pulmonary arterial hypertension (PAH).

Management of heart failure can be overwhelming for patients and their caregivers. To help address this, a new study has been launched assessing patient-facing mobile health technologies to improve adherence to medication and to self-care routines such as physical activity and following fluid and sodium restrictions. Known as the Care Optimization through Patient and Hospital Engagement Clinical Trial for Heart Failure (CONNECT HF), this quality improvement study is enrolling high-risk, hospitalized patients with acute heart failure and reduced ejection fraction.

Novartis reported better-than-expected first-quarter 2017 profits with CEO Joe Jimenez remaining confident the Swiss drugmaker would return to growth in 2018.

Novartis’ heart failure drug serelaxin flopped in a late-stage trial by not cutting cardiovascular death or slowing disease progression, marking the likely demise of a drug hopeful the Swiss firm had promoted as a potential blockbuster.

When it launched in February of 2015, Meerkat looked like it was going to be the hottest social application since Facebook. Two years later, Meerkat’s live-streaming platform is gone, taken down in the fall of 2016 after losing a battle for users with the similar (but Twitter-backed) platform Periscope. But although the players have changed, interest in live streaming has stuck around – and in some cases, grown quickly as users see the possibilities for it and existing social platforms begin adding it to their arsenal of features.

Shares of Arrowhead Pharmaceuticals Inc. sank one day after the company said it would stop developing all drugs being tested on humans.

A widely prescribed diabetes drug failed to reduce deaths or rehospitalizations in a study of patients with advanced heart failure.

Timely use of Novartis’ Entresto could prevent or postpone over 28,000 US deaths per year   EAST HANOVER, N.J., June 22, 2016 /PRNewswire/ — A new analysis published today in JAMA Cardiology has found that timely and broad adoption of Entresto® (sacubitril/valsartan) by all eligible heart failure patients with reduced ejection fraction (HFrEF) could prevent or […]

Eli Lilly and Co’s Jardiance diabetes drug slashed the risk of progressive kidney disease in adults with type 2 diabetes in a large trial.